Sertaconazole: In-Vitro Antifungal Activity Against Vaginal and Other Superficial Yeast Isolates

Abstract The in vitro susceptibilities of 183 clinical yeast isolates to sertaconazole (STZ) were compared to their susceptibilities to clotrimazole (CTZ), econazole (ECZ), ketoconazole (KTZ), miconazole (MNZ), fluconazole (FLZ), itraconazole (ITZ), tioconazole (TCZ), amphotericin B (AMB) and flucytosine (5FC) by using a commercial agar diffusion method. Strains were isolated from vaginal and other superficial clinical samples (18 species of Candida and five strains belonging to other yeast genera). Only one strain (0.5%) was resistant to STZ out of 87.4% of susceptible strains (n=160). The percentage of susceptible strains was higher than those obtained with the other agents evaluated and the percentage of resistant strains was lower than for most of the other antifun-gals. The pattern of susceptibility of C. albicans to STZ, TCZ, ITZ and CLZ was similar and superior to the pattern of susceptibility of this species to MNZ, ECZ, FLZ, 5FC and KTZ. C. dubliniensis was more susceptible to STZ, MNZ, MNZ, FLZ, ITZ, CLZ than to TCZ, ECZ, 5FC, AMB or KTZ. Ten susceptible strains to STZ were resistant to FLZ and one strain was resistant to ITZ. The overall antifungal activity of STZ in vitro against a wide range of clinically important yeasts from vaginal and cutaneous samples indicates the therapeutic potential of this agent for the treatment of infections caused by these fungi. However, the activity of STZ and the clinical value of in vitro data need to be verified in human clinical trials.

[1]  J. Pemán,et al.  Fluconazole Susceptibilities of Bloodstream Candidasp. Isolates as Determined by National Committee for Clinical Laboratory Standards Method M27-A and Two Other Methods , 1999, Journal of Clinical Microbiology.

[2]  G. Quindós,et al.  Multicenter evaluation of Neo-Sensitabs, a standardized diffusion method for yeast susceptibility testing. , 1999, Revista iberoamericana de micologia.

[3]  J. M. Torres-Rodríguez,et al.  Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. , 1999, Revista iberoamericana de micologia.

[4]  F. Dromer,et al.  Antifungal drug resistance in pathogenic fungi. , 1998, Medical mycology.

[5]  F. Odds.  Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes? , 1997, Revista iberoamericana de micologia.

[6]  C. Tur-Tur,et al.  Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. , 1997, Chemotherapy.

[7]  B. Gellin,et al.  Fungal infections: a growing threat. , 1996, Public health reports.

[8]  C. Tur,et al.  In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. , 1996, The Journal of antimicrobial chemotherapy.

[9]  A. Aller,et al.  Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.. , 1996, Chemotherapy.

[10]  B. Kullberg,et al.  [The changing pattern of Candida infections: different species and increased resistance]. , 1996, Nederlands tijdschrift voor geneeskunde.

[11]  J. M. Torres-Rodríguez,et al.  In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. , 1995, The Journal of antimicrobial chemotherapy.

[12]  J. Dupouy-Camet,et al.  Use of random amplified polymorphic DNA as a typing method for Candida albicans in epidemiological surveillance of a burn unit , 1995, Journal of clinical microbiology.

[13]  A. Sivayathorn,et al.  Prevalence of skin disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. , 1995, Annals of the Academy of Medicine, Singapore.

[14]  M. Pfaller,et al.  Epidemiology of fungal infections: the promise of molecular typing. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Pfaller,et al.  The use of molecular techniques in the epidemiology and control of infectious diseases. , 1995, Clinics in laboratory medicine.

[16]  A. Spinillo,et al.  Torulopsis glabrata Vaginitis , 1995, Obstetrics and gynecology.

[17]  T. G. Mitchell,et al.  Molecular mycology: DNA probes and applications of PCR technology. , 1994, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[18]  M. Pfaller,et al.  Epidemiology and control of fungal infections. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  G. Lemay,et al.  Application of biotyping and DNA typing of Candida albicans to the epidemiology of recurrent vulvovaginal candidiasis. , 1993, The Journal of infectious diseases.

[20]  J. Ortiz,et al.  In vitro activity of sertaconazole. , 1992, Arzneimittel-Forschung.

[21]  J. Ortiz,et al.  Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. , 1992, Arzneimittel-Forschung.

[22]  B. Dupont,et al.  In vitro antifungal activity of sertaconazole. , 1992, Arzneimittel-Forschung.

[23]  J. Ortiz,et al.  Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. , 1992, Arzneimittel-Forschung.

[24]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.

[25]  C. S. Chin,et al.  Torulopsis glabrata in vaginitis. , 1988, The Medical journal of Malaysia.

[26]  J. Casals,et al.  Tablet sensitivity testing on pathogenic fungi. , 1979, Journal of clinical pathology.